The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.
Richard D. Carvajal
Research Funding - MabVax
Mark Agulnik
Research Funding - MabVax
Christopher W. Ryan
Research Funding - MabVax
Mohammed M. Milhem
Research Funding - MabVax
Suzanne George
Research Funding - MabVax
Robin Lewis Jones
Research Funding - MabVax
Bartosz Chmielowski
Research Funding - MabVax
Brian Andrew Van Tine
Research Funding - MabVax
Hussein Abdul-Hassan Tawbi
Research Funding - MabVax
Anthony D. Elias
Research Funding - MabVax
William L. Read
Research Funding - MabVax
G. Thomas Budd
Research Funding - MabVax
Joe Hirman
Consultant or Advisory Role - MabVax
Paul Weiden
Consultant or Advisory Role - MabVax
Cathryn M. Bennett
Employment or Leadership Position - MabVax
Philip O. Livingston
Employment or Leadership Position - MabVax
David Hansen
Employment or Leadership Position - MabVax
Robert G. Maki
No relevant relationships to disclose
Gary K. Schwartz
Research Funding - MabVax
Rashmi Chugh
Research Funding - MabVax